Partial preservation of pancreatic β-cells by vanadium: Evidence for long-term amelioration of diabetes

Metabolism: Clinical and Experimental

Volumn 46, Issue 7, 1997, Pages 769-778

  Cam, M C ^a   Li, W M ^a   McNeill, J H ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

VANADIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FLUID INTAKE; GENETIC SUSCEPTIBILITY; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; INSULIN RELEASE; INSULIN RESPONSE; NONHUMAN; PANCREAS FUNCTION; PANCREAS ISLET BETA CELL; PANCREAS SECRETION; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES;

EID: 0030755933     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(97)90121-9     Document Type: Article

References (49)

1. Brichard SM, Henquin JC: The role of vanadium in the management of diabetes. Trends Pharmacol Sci 16:265-270, 1995
2. Shechter Y: Insulin-mimetic effects of vanadate. Possible implications for future treatment of diabetes. Diabetes 39:1-5, 1990
3. Heyliger CE, Tahiliani AG, McNeill JH: Effect of vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats. Science 227:1474-1477, 1985
4. Dai S, Thompson KH, McNeill JH: One-year treatment of streptozotocin-induced diabetic rats with vanadyl sulfate. Pharmacol Toxicol 74:101-109, 1994
5. Cam MC, Pederson RA, Brownsey RW, et al: Long-term effectiveness of oral vanadyl in streptozotocin-induced diabetes. Diabetologia 36:218-224, 1993
6. Fantus IG, Ahmad F, Deragon G: Vanadate augments insulin binding and prolongs insulin action in rat adipocytes. Endocrinology 127:2716-2725, 1990
7. Meyerovitch J, Farfel A, Sack J, et al: Oral administration of vanadate normalizes blood glucose levels in streptozotocin-treated rats. J Biol Chem 262:6658-6662, 1987
8. Okumura N, Shimazu T: Vanadate stimulates D-glucose transport into sarcolemmal vesicles from rat skeletal muscles. J Biochem 112:107-111, 1992
9. Miralpeix M, Carballo E, Bartrons R, et al: Oral administration of vanadate to diabetic rats restores liver 6-phosphofructo-2-kinase content and mRNA. Diabetologia 35:243-248, 1992
10. Rossetti L, Laughlin MR: Correction of chronic hyperglycemia with vanadate, but not with phlorizin, normalizes in vivo glycogen repletion and in vitro glycogen synthase activity in diabetic skeletal muscle. J Clin Invest 84:892-899, 1989
11. Blondel O, Bailbe D, Portha B: In vivo insulin resistance in streptozotocin-diabetic rats - Evidence for reversal following oral vanadate treatment. Diabetologia 32:185-190, 1989
12. Brichard SM, Ongemba LN, Girard J, et al: Tissue-specific correction of lipogenic enzyme gene expression in diabetic rats given vanadate. Diabetologia 37:1065-1072, 1994
13. Brichard SM, Okitolonda W, Henquin JC: Long term improvement of glucose homeostasis by vanadate treatment in diabetic rats. Endocrinology 123:2048-2053, 1988
14. Ramanadham S, Brownsey RW, Cros GH, et al: Sustained prevention of myocardial and metabolic abnormalities in diabetic rats following withdrawal from oral vanadyl treatment. Metabolism 38:1022-1028, 1989
15. Cam MC, Faun J, McNeill JH: Concentration-dependent glucose lowering effects of oral vanadyl are maintained following treatment withdrawal in streptozotocin-diabetic rats. Metabolism 44:332-339, 1995
16. Pederson RA, Ramanadham S, Buchan AMJ, et al: Long-term effects of vanadyl treatment on streptozotocin-induced diabetes in rats. Diabetes 38:1390-1395, 1989
17. Yilmaz MT: The remission concept in type 1 diabetes and its significance in immune intervention. Diabetes Metab Rev 9:337-348, 1993
18. Sprietsma JE, Schuitmaker GE: Diabetes can be prevented by reducing insulin production. Med Hypotheses 42:15-23, 1994
19. Gotfredsen CF, Buschard K, Frandsen EK: Reduction of diabetes incidence of BB Wistar rats by early prophylactic insulin treatment of diabetes-prone animals. Diabetologia 28:933-935, 1985
20. Atkinson MA, Maclaren NK, Luchetta R: Insulitis and diabetes in NOD mice reduced by prophylactic insulin therapy. Diabetes 39:933-937, 1990
21. Eizirik DL, Strandell E, Sandler S: Culture of mouse pancreatic islets in different glucose concentrations modifies B cell sensitivity to streptozotocin. Diabetologia 31:168-174, 1988
22. Sandler S, Andersson A: The partial protective effect of the hydroxyl radical scavenger dimethyl urea on streptozotocin-induced diabetes in vivo and in vitro. Diabetologia 23:374-378, 1982
23. Cam MC, McNeill JH: A sensitive radioimmunoassay optimized for reproducible measurement of rat plasma insulin. J Pharmacol Toxicol Methods 35:111-119, 1996
24. Mowry RW, Longley GB, Emmel VM: Only aldehyde-fuchsin made from pararosanilin stains pancreatic β-cell granules and elastic fibers in unoxidized microsection: Problems caused by mislabeling of certain basic fuchsins. Stain Technol 55:91-103, 1980
25. Thompson KH, McNeill JH: Effect of vanadyl sulfate feeding on susceptibility to peroxidative change in diabetic rats. Res Commun Chem Pathol Pharmacol 80:187-200, 1993
26. Mongold JJ, Cros GH, Vian L, et al: Toxicological aspects of vanadyl sulphate on diabetic rats: Effects of vanadium levels and pancreatic B-cell morphology. Pharmacol Toxicol 67:192-198, 1990
27. Dai S, Thompson KH, Vera E, et al: Toxicity studies on one-year treatment of non-diabetic and STZ-diabetic rats with vanadyl sulphate. Pharmacol Toxicol 75:265-273, 1994
28. Cam MC, McNeill JH: The antidiabetic effects of vanadium treatment in STZ-diabetic rats are independent of its effects on reducing food intake, (submitted)
29. Malabu UH, Dryden S, McCarthy HD, et al: Effects of chronic vanadate administration in the STZ-induced diabetic rat. Diabetes 43:9-15, 1994
30. Lucke S, Besch W, Kauert C, et al: The endocrine pancreas of BB/OK-rats before and at diagnosis of hyperglycemia. Exp Clin Eridocrinol 91:161-170, 1988
31. Nakajima K, Morikawa A, Makino I: Natural history of β-cell dysfunction in spontaneously diabetic Chinese hamsters. Diabetes Res Clin Pract 24:131-142, 1994
32. Tuomilehto J, Wolf E: Primary prevention of diabetes mellitus. Diabetes Care 10:238-248, 1987
33. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28:1039-1057, 1979
34. Child CG, Frey CF, Fry WJ: A reappraisal of removal of ninety-five percent of the distal portion of the pancreas. Surg Gynecol Obstet 129:49-56, 1969
35. Kauffmann F, Rodriguez RR: Subtotal pancreatectomy in five different rat strains: Incidence and course of development of diabetes. Diabetologia 27:38-43, 1984
36. Bonnevie-Nielsen V, Steffes MW, Lernmark A: A major loss in islet mass and β-cell function precedes hyperglycemia in mice given multiple low doses of streptozotocin. Diabetes 30:424-429, 1981
37. Junod A, Lambert AE, Stauffacher W, et al: Diabetogenic action of streptozotocin: Relationship of dose to metabolic response. J Clin Invest 48:2129-2139, 1969
38. Le PH, Leiter EH, Leyendecker JR: Genetic control of susceptibility to streptozotocin diabetes in inbred mice: Effect of testosterone and H-2 haplotype. Endocrinology 116:2450-2455, 1985
39. Serradas P, Bailbe D, Portha B: Long-term gliclazide treatment improves the in vitro glucose-induced insulin release in rats with type 2 (non-insulin-dependent) diabetes induced by neonatal streptozotocin. Diabetologia 32:577-584, 1989
40. Bonnevie-Nielsen V: The endocrine pancreas. Aspects of β-cell function in relation to morphology, insulin secretion and insulin content. Scand J Clin Lab Invest 183:1-47, 1986
41. McCulloch DK, Koerker DJ, Kahn SE, et al: Correlations of in vivo β-cell function tests with β-cell mass and pancreatic insulin content in streptozocin-administered baboons. Diabetes 40:673-679, 1991
42. Van Gompel J, Mahler T, De Paepe M, et al: Comparison of in situ hybridization and immunocytochemistry for the detection of residual beta cells in the pancréas of streptozotocin-treated diabetic rats. Acta Diabetol 30:118-122, 1993
43. Shah SC, Malone JI, Simpson NE: A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes mellitus. N Engl J Med 320:550-554, 1989
44. Ar'Rajab A, Ahren B: Long-term diabetogenic effect of streptozotocin in rats. Pancreas 8:51-57, 1993
45. Portha B, Picon L: Insulin treatment improves the spontaneous remission of neonatal streptozotocin diabetes in the rat. Diabetes 31:165-169, 1982
46. Vlahos WD, Seemayer TA, Yale JF: Diabetes prevention in BB rats by inhibition of endogenous insulin secretion. Metabolism 40:825-829, 1991
47. Leahy JL, Bumbalo LM, Chen C: Diazoxide causes recovery of β-cell glucose responsiveness in 90% pancreatectomized diabetic rats. Diabetes 43:173-179, 1994
48. Sako Y, Grill VE: Coupling of β-cell desensitization by hyperglycemia to excessive stimulation and circulating insulin in glucoseinfused rats. Diabetes 39:1580-1583, 1990
49. Bendayan M, Gringas D: Effect of vanadate administration on blood glucose and insulin levels as well as on the exocrine pancreatic function in streptozotocin-diabetic rats. Diabetologia 32:561-567, 1989